Vivesto — Share Issue/Capital Change 2022

Mar 3, 2022

Press Release

03 March 2022 14:37:00 CET

oasmia

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTIONS IN WHICH DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS APPLY. PLEASE SEE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

On 19 January 2022, Oasmia Pharmaceutical AB ("Oasmia" or the "Company") announced that the Board of Directors had resolved to carry out a rights issue of approximately SEK 151 million (the "Rights Issue"). The Board of Directors' resolution of the Rights Issue was approved by the Extraordinary General Meeting held on 21 February 2022. The prospectus that has been prepared in connection with the Rights Issue (the "Prospectus") has today, the 3 March 2022, been approved and registered by the Swedish Financial Supervisory Authority, and is available on Oasmia's website, www.oasmia.com, as well as on Danske Bank's website, www.danskebank.se/prospekt.

Advisers

In connection with the Rights Issue, Oasmia has appointed Danske Bank A/S, Danmark, Sverige Filial as financial adviser and Sole Bookrunner. Törngren Magnell & Partners Advokatfirma KB acts as legal adviser to the Company and Schjødt acts as legal adviser to Danske Bank.

FOR MORE INFORMATION:

Oasmia Pharmaceutical AB

Francois Martelet, Chief Executive Officer

Telefon: +46 18-50 54 40

E-mail: IR@oasmia.com

Consilium Strategic Communications

Jonathan Birt, Ashley Tapp

Telefon: +44 (0)20 3709 5700

E-mail: oasmia@consilium-comms.com

About Oasmia

Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing

Oasmia Pharmaceutical | Vallongatan 1 | SE-752 28 Uppsala

---

Press Release 03 March 2022 14:37:00 CET

oasmia

pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia's shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares, paid-up subscribed share, subscription rights or other securities in Oasmia Pharmaceutical AB. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in Oasmia will only be made through the Prospectus that Oasmia published today. The Prospectus is only available and published in a Swedish version.

The information in this press release may not be published, copied, reproduced or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "USA"), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law.

This press release does not constitute an offer or invitation to acquire or subscribe for shares or other securities in the USA. No shares, paid-up subscribed shares, subscription rights or other securities issued by the Company (the "Securities") have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the Rights Issue or the accuracy or reliability of the Prospectus. To assert the contrary is a criminal act in the USA.

This press release is not a Prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State, other than Sweden, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of the Prospectus Regulation.

Oasmia Pharmaceutical | Vallongatan 1 | SE-752 28 Uppsala

---

Press Release

03 March 2022 14:37:00 CET

oasmia

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Matters discussed in this press release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements.

Attachments

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Oasmia Pharmaceutical | Vallongatan 1 | SE-752 28 Uppsala